Morphic Medical Announces NUB Status One for RESET® Endoscopic Device Therapy in Germany
Februar 3, 2026
Read More »Februar 3, 2026
Read More »September 23, 2025
Read More »September 12, 2025
Read More »September 9, 2025
Read More »August 5, 2025
Morphic Medical, an innovative MedTech company that has pioneered minimally invassive treatment of obestiy and cardiometabolic disorders, today announced a leadership transition as part of its continued evolution and growth strategy.
Read More »Juli 9, 2025
Morphic Medical, creator of the world’s first medical device designed to target the underlying cause of obesity and type 2 diabetes, today announced CE (Conformité Européenne) Mark approval for the RESET® System designed to provide patients living with obesity and metabolic disorders such as Type 2 Diabetes (T2D) with the first incision-free.
Read More »Dezember 13, 2023
Morphic Medical today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors
Read More »Juli 10, 2023
GI Dynamics is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®.
Read More »April 4, 2023
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology.
Read More »Februar 13, 2023
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.
Read More »Juli 14, 2022
Studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity.
Read More »Juni 15, 2022
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints. Findings Presented at DDW 2022 BOSTON.
Read More »Januar 31, 2022
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.
Read More »November 5, 2020
Joseph Virgilio appointed as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors, and Ginger Glaser as non-executive director to the Board.
Read More »September 10, 2020
Initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), the Company’s majority stockholder.
Read More »Juli 15, 2020
Update regarding the removal of the Company from the Official List of the Australian Securities Exchange (“ASX”).
Read More »Juli 15, 2020
Crystal Amber has provided a notice to convert all of the outstanding principal and accrued interest owed under the June 2017 Note.
Read More »Juli 1, 2020
Update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal Amber”).
Read More »Juni 22, 2020
Resolution approved to delist Company from the Official List of the Australian Securities Exchange (“ASX”) (“Official List”).
Read More »Juni 19, 2020
Read More »
